Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update
Date:8/7/2008

red to $27.4 million for the six months ended June 30, 2007, and include $3.2 million and $4.5 million in non-cash stock-based compensation in the 2008 and 2007 periods, respectively.

Operating expenses during the quarter primarily related to the continued development and commercial preparations to launch, Zingo, a fast-acting, needle-free, local anesthetic, for the pediatric indication. Additional operating expenses related to the ongoing development of Adlea, which is being evaluated in Phase 3 trials for the treatment of acute pain following total knee replacement surgeries and bunionectomy surgeries.

For the second quarter of 2008, the net loss was $21.9 million, or $0.54 per share. In the second quarter of 2007, the net loss was $13.8 million, or $0.51 per share. The net loss for the six months ended June 30, 2008 was $43.4 million, or $1.08 per share, and for the six months ended June 30, 2007, the net loss was $25.5 million or $0.93 per share.

As of June 30, 2008, cash, cash equivalents and investments were $48.7 million compared to $90.8 million at December 31, 2007. The company believes it has sufficient resources to fund anticipated expenses for the remainder of 2008 and into 2009.

Commercial and Product Development Updates:

Zingo

-- Following the Zingo U.S. commercial launch in late June, Anesiva began

supplying hospitals in its target pediatric market. The early phase of

the Zingo launch is focused on supporting initial product experiences

and formulary review and acceptance processes in these institutions.

Commenting on the initial Zingo launch, Nancy E. Donahue, senior vice president, sales and marketing, said, "While it is too early to provide meaningful sales metrics as we are just six weeks into the launch, initial qualitative feedback from healthcare providers who have used Zingo suggests that they are very pleased with its performance and ease of use. We continue to
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... , July 30, 2014   Wyle ... Fully Integrated Lifecycle Mission Support Services (FILMSS) contract ... (NASA). Under the terms of the contract, Wyle ... at Moffett Field, Calif. In particular, Wyle will ... flight development projects on the International Space Station ...
(Date:7/30/2014)... Vycom announces the addition of Thermax PVC ... Factory Mutual (FM) 4910 fire propagation and smoke generation ... process tools, fume hoods, furniture and cabinetry. These criteria ... wafers used in electronic chip manufacturing. , ... excellent workability and superior aesthetics. It is available in ...
(Date:7/30/2014)... July 30, 2014 Researchers often use ... biology, but such devices can do much more ... As such, researchers have looked to patterned assemblies ... metabolic engineering to characterize – and potentially ... devices are envisioned to recreate animal and human ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4
... LEUVEN, Belgium and LUND, Sweden, September 7 ... Anticoagulant Into Phase,II Clinical Development ThromboGenics NV ... disease, and co-development partner, BioInvent,International (Nordic Exchange: BINV), ... initial follow-up of all volunteers,in the first Phase ...
... 6 Globally, approximately 418 billion,people are currently ... costs of hepatitis in the 21st century cannot ... a,new report by Kalorama Information. Paradoxically, despite ... necessary steps to contain hepatitis. Yet the incidence ...
... VRUS ) and Roche (OTC: RHHBY) announced ... the treatment of chronic hepatitis C,virus (HCV) will ... Hepatitis C,Virus and Related Viruses being held from ... of PSI-6130, is an oral cytidine nucleoside,analog polymerase ...
Cached Biology Technology:ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 5Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
(Date:7/31/2014)... can affect animal movement and communication, with unknown ecological ... and the cole Pratique des Hautes tudes (EPHE) CRIOBE ... development and increases larval mortality in sea hares. , ... used in this study) usually hatch from their ... alga but this study, conducted in a coral reef ...
(Date:7/31/2014)... new meta-analyses involving tree nuts (almonds, Brazil nuts, cashews, ... recently published in the online publications, British Medical ... ONE (ii). The BMJ Open article ... syndrome (MetS) criteria and showed that tree nut consumption ... blood glucose. The PLOS ONE article focused ...
(Date:7/30/2014)... paving the way for a breakthrough that may ... exposed to poisonous chemicalsparticularly those in pesticides and ... current issue of the journal ChemBioChem ... compounds commonly used in pesticides and warfare agents. ... of Engineering Associate Professor of Chemical and Biological ...
Breaking Biology News(10 mins):Boat noise impacts development and survival of sea hares 2New international tree nut council study looks at nuts, diabetes and metabolic syndrome 2Engineering a protein to prevent brain damage from toxic agents 2
... Washington, D.C. (September 14, 2010) -- Piezoelectric materials ... electrical field. And vice-versa, they contract or expand when ... from the Greek word meaning to squeeze or press, ... was discovered in several crystals in 1880. But in ...
... Charlotte, North Carolina is a rapidly growing city. Charlotte ... that as a contradiction. , In Charlotte, there are ... shadow of the towers of the nation,s second largest ... undeveloped land within the city,s boundaries. Social scientists find ...
... EVANSTON, Ill. --- It seems the old nature versus ... study of men in the Philippines makes a strong case ... that rapid weight gain in the first six months of ... experienced rapid growth as babies -- an indication that they ...
Cached Biology News:Lead-free piezoelectric materials of the future 2Interdisciplinary research looks at Charlotte's green mystery 2Interdisciplinary research looks at Charlotte's green mystery 3Interdisciplinary research looks at Charlotte's green mystery 4Interdisciplinary research looks at Charlotte's green mystery 5Interdisciplinary research looks at Charlotte's green mystery 6Male maturity shaped by early nutrition 2Male maturity shaped by early nutrition 3
Functionally tested for consistent G-banding of chromosomes....
... BacVector Insect Cell Medium is optimized ... Ea4 Insect Cells. In this protein-free medium, ... 1 * 107 cells/ml with viabilities above ... plaque assays, where color from X-gluc staining ...
... Grace's Insect Medium is formuatled for ... including Sf9 and Sf21 cells. Grace's ... transfectioin because it does not contain ... interfere with transfection. Grace's Insect Medium, ...
TNM-FH Insect Medium 1 liter...
Biology Products: